This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Epidemic Increases In Melanoma Rates Three Of Four Americans Surveyed Have Never Had Skin Cancer Examination

Stocks in this article: MELA

IRVINGTON, N.Y., Feb. 21, 2013 /PRNewswire/ -- MELA Sciences, Inc. (NASDAQ: MELA). Despite alarming increases in skin cancer rates in the U.S., only 24% of American adults have had a skin check by a dermatologist. This statistic is one of several important findings from a survey conducted online by Harris Interactive® that reveals insights into behaviors regarding skin cancer detection and illustrates the urgency around improved preventative care. The study was conducted on behalf of MELA Sciences, Inc. from January 29-31, 2013, among 2,109 Americans ages 18 and older.

(Logo: )

Additional key findings:

  • Only 23% of Americans perform monthly mole self-checks
  • 37% of Americans believe they are not at risk for skin cancer -- in spite of industry statistics that report 1 in 5 Americans will develop skin cancer annually
  • While 85% of U.S. adults correctly believe that moles are often pre-cursors to melanoma, the deadliest form of skin cancer, 20% believe that moles "are simply beauty marks"

"While many forms of cancer are on the decline, melanoma continues to rise and in fact, is the leading cause of cancer death in women ages 25 to 30 and second only to breast cancer in women ages 30 to 34," said Dr. Joseph Gulfo, President and CEO of MELA Sciences, Inc. "We have a tremendous opportunity to spread awareness and change the course of the disease by advocating for the detection of melanoma at its most curable stage, and with this survey, we'll draw attention to the importance of annual skin checks in the fight against melanoma."

MELA Sciences, Inc. is the pioneer company that developed MelaFind®, the first and only FDA-approved diagnostic tool to detect melanoma at its most curable stage. The patient survival rate is nearly 100% if melanoma is found when limited to the outer-most layer of the skin; once the cancer is advanced, the five year survival rate is generally 15-20%. MelaFind® sees 2.5 mm under the skin and uses multi-spectral light technology to provide dermatologists with additional information when deciding which ambiguous moles to biopsy during skin examinations. In the MelaFind® Pivotal Trial, which was the largest positive prospective clinical study ever conducted in melanoma detection, MelaFind® detected 98.3% of the melanomas.

1 of 3

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs